Stanford scientists in Dr. Liqun Luo's laboratory have developed a patented method for site-directed somatic cell recombination and concurrent labeling of "knock in" cells.
Researchers in the laboratory of Michael Cleary at Stanford University have developed a mouse that lacks the transcription factor Pbx1. Pbx1 is a proto-oncogene that was originally discovered at the site of chromosomal translocations in pediatric acute leukemia.
Researchers in Dr. Mark Kay's laboratory at Stanford University have designed a new liver-specific expression cassette for inserting genes into double-stranded AAV (adeno-associated virus) vectors for gene therapy.
Rat monoclonal antibody BZ332 specifically recognizes human serpentine protein CMKLR1. CMKLR1 is a novel protein possessing high homology with members of the chemoattractant receptor family, and binds the chmoattractant chemerin.
Monoclonal antibody that recognizes MLL, an oncoprotein that is mutated in a broad subset of pediatric and adult leukemias. MLL protein displays histone methyltransferase activity.
EDL (gene nomenclature, LIPG; protein, EL), gene targeted, mouse bred to homozygosity for the purposes of biological studying of EDL and the role it plays in lipoprotein metabolism.
The fosGFP Mouse was created to address a fundamental question in neuroscience and physiology: following a behavioral task or exposure to a drug, what are the changes in physiological properties of activated neurons and cells?
Rat monoclonal antibody isotype IgG2a (clone #153) recognizes the HA peptide sequence [YPYDVPDYA] derived from the influenza hemagglutinin protein. The HA peptide can be added to unrelated proteins through recombinant techniques.
The invention consists of a plasmid encoding enhanced green fluorescent
protein (GFP) modified with a short targeting sequence appended to its
carboxyterminus. This targeting sequence converts the normally stable
Researchers in the laboratory of Dr. Michael Cleary at Stanford University have developed anti-Meis monoclonal antibodies to study transcriptional regulation, embryonic development, and tissue homeostasis.
The general purposes of this invention are 1) to provide bulk quantities of relatively pure soluble antigens of the human major histocompatibility complex; and 2) to determine whether or not soluble forms of the normally surface-bound HLA antigens could be used for diagnostic